David Dodds has lead interdisciplinary process development groups using biological methods to perform organic synthesis for over 25 years.  Most recently, David established Dodds & Associates, providing technical management and diligence to start-up pharma, biotech, and industrial biotech companies, primarily focusing on the use of biological methods to produce non-fuel chemicals.  Prior to Dodds and Associates, he was Director of Fermentation and Biocatalysis Development at Bristol-Meyrs Squibb. He led chemical process development, molecular biology, industrial fermentation, and GMP analytical services, supporting both Discovery and Production. Before BMS, David established a new group within Chemical Process Development at Schering-Plough. His group introduced biocatalysis in over a dozen projects at scales ranging from lab-bench scale synthesis of drug metabolites, to GMP pilot-plant batches providing intermediates for clinical compounds, two of which were approved.  Under David's leadership, the group filed 13 patent disclosures and produced a total of 37 public presentations and publications.  David obtained his Ph.D. in synthetic organic chemistry from the University of Toronto.